Given management said they wouldn't entertain any offers until after the PMS trial design is agreed and ready to start, it appears this event is a significant turning point in the value of the company. If I think back to the recent post by Hottod of Biogen's CEO talking about looking for companies preferably in the Phase 2 stage because they're cheaper than Phase 3 companies, perhaps having an agreed Phase 3 trial ready to start is enough of a catalyst to spark significant offers from suitors. Logically you'd think completing a Phase 3 trial successfully would be the main value amplifier. But Neuren reiterated they are not interested in marketing and selling the drug, and I think they'd like to wrap this up early so the buyer can have a smoother run bringing the drug to market.
With that in mind, if the agreed trial design is the point where Neuren starts to entertain offers, maybe it would be a good time to announce the new indications then to bolster the value of the company before or during preliminary discussions.
Add to My Watchlist
What is My Watchlist?
